Long-term survival of uveal melanoma patients with respect to clinical, hemodynamic and morphological characteristics of the tumor

   Purpose. Evaluation of long-term results of uveal melanoma (UM) treatment in patients depending on clinical, hemodynamic and morphological parameters of the tumor.

   Material and methods. Long-term results of treatment were analyzed in 394 UM patients aged 17 to 82 (mean age 53.1 ± 13.2). The median follow-up was 56 months. Group A (n = 242, organ-preserving treatment) consisted of patients with a tumor height of 5.0 ± 1.8 mm and base diameter of 12.7 ± 2.9 mm. Group B (n = 152, enucleation) included patients with 8.3 ± 2.8 mm tumor height and 15.2 ± 4.1 mm base diameter. Overall survival and disease-dependent survival were determined.

   Results. The cumulative 3-, 5-, and 7-year survival rates of patients with choroidal melanoma were 91.6 ± 1.7, 84.0 ± 2.5, 74.0 ± 3.8 % , and those with ciliochoroidal melanoma were 84.2 ± 5.6, 79.9 ± 5.8, and 53.0 ± 14.7 %, respectively (p = 0.048). In group A, the 5-year survival rates of patients with mushroom-shaped and irregular forms were 80.6 ± 5.9 and 74.6 ± 10.9 %, respectively, and 96.0 ± 2.0 % for dome-shaped UM. The worst 5-year survival rates were shown by patients with tumor stabilization, and the best ones, by patients with complete tumor resorption (x2 = 6.880, p = 0.008). Patients with post-radiation optical neuropathy (n = 193) had better 5-year survival rates (90.3 ± 2.9 %) than patients (n = 49) without neuropathy (77.5 ± 8.0 %). In group B, cumulative 1-year survival was 95.2 ± 1.9 %, 2-year survival, 89.2 ± 2.8 % , 3-year survival, 84.9 ± 2.9 % , 4-year survival, 81.8 ± 3.6 %, 5-year survival, 77.5 ± 4.0 % , 6-year survival, 67.9 ± 4.8 % , and 7-year survival was 64.7 ± 5.2 %. In epithelioid-cell, mixed-cell, and spindle-cell types of UM, the 5-year survival rates were 46.3 ± 12.0, 70.7 ± 8.0 %, and 84.8 ± 5.4 %, respectively (x2 = 11.571, p = 0.004). The 5-year survival rate of patients with extrascleral growth was 56.0 ± 10.4 % and without extrascleral growth it was 81.7 ± 4.0 %.

   Conclusion. In organ-preserving treatment, the combination of prognostic factors allows us to stratify the patients based on the risk of early metastasis, which allows for personalized dynamic monitoring, taking into account the vital prognosis of a particular patient.

1. Damato B. E., Heimann H., Kalirai H., Coupland S. E. Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival. JAMA Ophthalmol. 2014; 132 (5): 605–13. doi: 10.1001/jamaophthalmol.2014.77

2. Damato B. Does ocular treatment of uveal melanoma influence survival? Br. J. Cancer. 2010; 103 (3): 285–90. doi: 10.1038/sj.bjc.6605765

3. Singh A. D., Zabor E. C., Radivoyevitch T. Estimating cured fractions of uveal melanoma. JAMA Ophthalmol. 2021; 139 (2): 174–181. doi: 10.1001/jamaophthalmol.2020.5720

4. Амирян А. Г. Факторы прогноза увеальной меланомы / А. Г. Амирян, С. В. Саакян // Вестник офтальмологии. – 2015. – 131 (1): 90–5. [Amiryan A. G., Saakyan S. V. Prognostic factors for uveal melanoma. Vestnik Oftal’mologii. 2015; 131 (1): 90–5 (in Russian)]. doi: 10.17116/oftalma2015131190-94

5. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch. Ophthalmol. 2006; 124 (12): 1684–93.

6. Саакян С. В. Особенности метастатического поражения и выживаемости больных увеальной меланомой в зависимости от метода проведенного лечения / С. В. Саакян, О. Г. Пантелеева, Т. В. Ширина // Российский онкологический журнал. – 2012. – 5 (2): 55–8. [Saakyan S. V., Panteleeva O. G., Shirina T. V. Metastatic disease characteristics and survival of patients with uveal melanoma depending on the method of treatment of the primary tumor. Rossijskij onkologicheskij zhurnal. 2012; 5 (2): 55–8 (in Russian)].

7. Kujala E., Mäkitie T., Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003; 44 (11): 4651–9. doi: 10.1167/iovs.03-0538

8. Цыганков А. Ю. Роль клинических, патоморфологических и молекулярно-генетических факторов в выживаемости больных увеальной меланомой / А. Ю. Цыганков [и др.] // Эффективная фармакотерапия. – 2016. – 39: 52–59. [Tsygankov A. Iu., Saakyan S. V., Amiryan A. G., Sklyarova N. V., Zaletaev D. V. A role of clinical, pathomorphology and genetic factors in survival of patients with uveal melanoma. Effective pharmacotherapy journal. 2016; 39: 52–9 (in Russian)].

9. Bergman L., Nilsson B., Lundell G., Lundell M., Seregard S. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005; 112 (5): 834–40. doi: 10.1016/j.ophtha.2004.11.038

10. Yonekawa Y., Kim I. K. Epidemiology and management of uveal melanoma. Hematol. Oncol. Clin. North Am. 2012; 26 (6): 1169–84. doi: 10.1016/j.hoc.2012.08.004

11. Papageorgiou K. I., Cohen V. M., Bunce C., Kinsella M., Hungerford J. L. Predicting local control of choroidal melanomas following. Ru plaque brachytherapy. Br. J. Ophthalmol. 2011; 95 (2): 166–70. doi: 10.1136/bjo.2009.176198

12. Kaiserman I., Anteby I., Chowers I., et al. Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. Br. J. Ophthalmol. 2004; 88 (7): 892–5. doi: 10.1136/bjo.2003.036285

13. Нероев В. В. Выживаемость больных увеальной меланомой в отдаленные сроки после энуклеации в зависимости от молекулярно-генетических аберраций / В. В. Нероева [и др.] // Альманах клинической медицины. – 2018. – 46 (4): 338–46. [Neroev V. V., Saakyan S. V., Amiryan A. G., et al. Long-term survival of uveal melanoma patients after enucleation, depending on molecular genetic aberrations. Al'manakh klinicheskoj meditciny. 2018; 46 (4): 338–46 (in Russian)]. doi:10.18786/2072-0505-2018-46-4-338-346

14. Панова И. Е. Клинико-инструментальные критерии риска метастазирования меланомы хориоидеи / И. Е. Панова [и др.] // Российский офтальмологический журнал. – 2019. – 12 (3): 30–6. [Panova I. E., Vlasova O. S., Gyuntner E. I., Samkovich E. V., Shamanova A. Yu. Determining the risk of metastasis of choroidal melanoma: clinical and instrumental criteria. Russian Ophthalmological Journal. 2019; 12 (3): 30–6 (in Russian)]. doi:10.21516/2072-0076-2019-12-3-30-36

15. Damato B. E., Coupland S. E. Ocular melanoma. Saudi J. Ophthalmol. 2012; 26 (2): 137–44. doi: 10.1016/j.sjopt.2012.02.004

16. Missotten G. S., Keunen J. E. Screening for uveal melanoma metastasis. Literature review. Bull. Soc. Belge Ophtalmol. 2004; (294): 13–22. PMID: 15682915.

17. Zardi E. M., Cacioli G., Giorgi C., Rafano Carnà E. P., Zardi D. M. Rare left ventricular metastasis from uveal melanoma. Cardiol. J. 2017; 24 (6): 712–4. doi: 10.5603/CJ.2017.0150

18. Kodjikian L., Grange J. D., Rivoire M. Prolonged survival after resection of liver metastases from uveal melanoma and intra-arterial chemotherapy. Graefes Arch. Clin. Exp. Ophthalmol. 2005; 243 (6): 622–4. doi: 10.1007/s00417-004-1057-x

19. Cai L., Paez-Escamilla M., Walter S. D., et al. Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma. Am. J. Ophthalmol. 2018; 195: 154–60. doi: 10.1016/j.ajo.2018.07.045

20. Rowcroft A., Loveday B. P. T., Thomson B. N. J., Banting S., Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020; 22 (4): 497–505. doi: 10.1016/j.hpb.2019.11.002

21. Shields C. L. The hunt for the secrets of uveal melanoma. Clin. Exp. Ophthalmol. 2008; 36 (3): 277–80. doi: 10.1111/j.1442-9071.2008.01717.x

22. Miguel D., de Frutos-Baraja J. M., López-Lara F., et al. Radiobiological doses, tumor, and treatment features influence on outcomes after episcleral brachytherapy. A 20-year retrospective analysis from a single-institution: part II. J. Contemp. Brachytherapy. 2018; 10 (4): 347–59. doi: 10.5114/jcb.2018.77955

23. Coupland S. E., Campbell I., Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. Ophthalmology. 2008; 115 (10): 1778–85. doi: 10.1016/j.ophtha.2008.04.025

24. Нероев В. В. Факторы риска экстрабульбарного роста после локального лечения увеальной меланомы / В. В. Нероев [и др.] // Вестник офтальмологии. – 2011. – 127 (5): 21–5. [Neroev V. V., Saakyan S. V., Amiryan A. G., Valsky V. V. Risk factors of extraocular spread after local treatment of uveal melanoma. Vestnik oftal'mologii. 2011; 127 (5): 21–5 (in Russian)].

25. Цыганков А. Ю. Роль патоморфологических и молекулярно-генетических факторов в развитии экстрабульбарного роста увеальной меланомы / А. Ю. Цыганков, А. Г. Амирян, С. В. Саакян // Современные технологии в медицине. – 2016. – 8 (2): 76–83. [Tsygankov A. Yu., Amiryan A. G., Saakyan S. V. The role of pathologic and molecular genetic factors in development of uveal melanoma extrabulbar growth. Sovremennye tehnologii v medicine. 2016; 8 (2): 76–83 (in Russian)]. doi:10.17691/stm2016.8.2.11